Skip to Main Content
Tao Zou, M.D.,  Ph.D.

Tao Zou, M.D., Ph.D.

Titles and Appointments

Assistant Professor

School
Graduate School
Department
Internal Medicine | Harold C. Simmons Comprehensive Cancer Center
Graduate Programs
Cancer Biology, Immunology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Tao Zou, M.D., Ph.D, is an Assistant Professor in the Department of Internal Medicine at the UT Southwestern Medical Center and a member of the Division of Hematology and Oncology. He also has a secondary appointment in the Department of Immunology and is a member of the Hamon Center for Therapeutic Oncology Research. 

    Dr. Zou earned his medical degree and doctoral degree in Immunology at the University of Pennsylvania Perelman School of Medicine. After completing his residency in Internal Medicine at Massachusetts General Hospital (MGH), he received advanced training in Medical Oncology at Dana-Farber Cancer Institute (DFCI)/MGH Cancer Center. Concurrently, Dr. Zou completed a research fellowship in Cancer Biology at DFCI/Harvard Medical School. 

    Dr. Zou is certified in Medical Oncology by the American Board of Internal Medicine. He joined the UT Southwestern faculty in 2025. 

    Dr. Zou is also a practicing thoracic medical oncologist. In this role, he treats patients with a range of thoracic malignancies with a particular interest in cancer immunotherapy. Concurrent with his clinical practice, Dr. Zou's laboratory research seeks to leverage the immune system to fight lung cancer. He is especially interested in repurposing innate immune signaling pathways and the adaptive T cell response against various subtypes of non-small cell lung cancer. 

  • Education
    Graduate School
    Perelman School of Medicine at the University of Pennsylvania (2012)
    Medical School
    Perelman School of Medicine at the University of Pennsylvania (2013)
    Residency
    Massachusetts General Hospital (2016), Internal Medicine
    Fellowship
    Dana-Farber Cancer Institute (2021), Hematology Oncology
  • Research Interest
    • Immunology
    • Lung Cancer Biology
  • Publications

    Star Featured Publications

    PACT prevents aberrant activation of PKR by endogenous dsRNA without sequestration.
    Ahmad S, Zou T, Hwang J, Zhao L, Wang X, Davydenko A, Buchumenski I, Zhuang P, Fishbein AR, Capcha-Rodriguez D, Orgel A, Levanon EY, Myong S, Chou J, Meyerson M, Hur S, Nat Commun 2025 Apr 16 1 3325
    XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells.
    Zou T, Zhou M, Gupta A, Zhuang P, Fishbein AR, Wei HY, Capcha-Rodriguez D, Zhang Z, Cherniack AD, Meyerson M, Cell Rep 2024 Feb 43 2 113600
    Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
    Zou T, Meyerson M, Cancer Res 2019 Mar 79 6 1038-1040
    Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.
    Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, Ivan AP, Buchumenski I, Berger AC, Goldstein JT, Cherniack AD, Vazquez F, Tsherniak A, Levanon EY, Hahn WC, Meyerson M, Nat Commun 2018 Dec 9 1 5450
    Mechanistic Insights into Transmissible Cancers of Mammals.
    Bullman S, Zou T, Meyerson M, Cancer Cell 2018 Apr 33 4 543-544
    Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
    Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK, Neuberg DS, Fathi AT, Cancer 2017 Jul 123 13 2561-2569
    More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer.
    Zou T, Awad MM, Ann Oncol 2017 Apr 28 4 685-687
    Both retention and recirculation contribute to long-lived regulatory T-cell accumulation in the thymus.
    Yang E, Zou T, Leichner TM, Zhang SL, Kambayashi T Eur. J. Immunol. 2014 Jun
    Diacylglycerol kinase ζ limits the generation of natural regulatory T cells.
    Schmidt AM, Zou T, Joshi RP, Leichner TM, Pimentel MA, Sommers CL, Kambayashi T, Sci Signal 2013 Nov 6 303 ra101
    Cutting edge: IL-2 signals determine the degree of TCR signaling necessary to support regulatory T cell proliferation in vivo.
    Zou T, Satake A, Corbo-Rodgers E, Schmidt AM, Farrar MA, Maltzman JS, Kambayashi T J. Immunol. 2012 Jul 189 1 28-32